Scoping review reveals probiotics may aid immune responses and gastrointestinal health in tuberculosis treatment, suggesting further research on long-term effects is needed.
This scoping review aims to synthesize the current clinical evidence on probiotics used in tuberculosis (TB). Systematic literature searches were conducted across PubMed, Scopus, and Embase databases to identify all studies using probiotics in TB. A total of six studies conducted between 2016 and 2023 were found and included in this review. All the studies incorporated probiotics supplementation not beyond the intensive phase of antitubercular therapy (ATT), ranging from three to eight weeks. Five out of six included studies focused on pulmonary TB. Probiotics alleviate adverse gastrointestinal and hepatic drug reactions, modulate gut microbiota, enhance barrier function, and influence immune responses. Therefore, probiotics are a potential adjunct therapy during the intensive phase of ATT. However, their long‐term effects remain unexplored, highlighting the future research scope for well‐designed longitudinal studies to explore their sustained benefits.
No takes yet. Share an insight, caveat, or question.
Baral et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: